Medco Health Solutions Inc

Medco Health Solutions — Thomas Weisel Partners Healthcare Conference 2009

22 slides from Medco Health Solutions's conference presentation, Sep 11, 2009

  1. Slide 1: Advancing Pharmacy - Reforming Healthcare

    Slide 1: Advancing Pharmacy - Reforming Healthcare

    Advancing Pharmacy - Reforming Healthcare Thomas Weisel Partners Healthcare Conference 2009 September 11, 2009 Brian T. Griffin Group President, Health Plans Richard J. Rubino SVP, Finance and CFO

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. No

  3. Slide 3: Who is Medco

    Slide 3: Who is Medco

    Who is Medco Ranked #45 on the Fortune 100* List $51.3 Billion in Revenues for 2008 $29.8 Billion YTD June 2009 60+ Million Members Largest Independent PBM Measured by Drug Spend Largest Specialty Pharmacy Largest Mail-Order Pharmacies in the World Leader in Clinical Innovation *2008 Rankings

  4. Slide 4: What is Driving Our Growth

    Slide 4: What is Driving Our Growth

    What is Driving Our Growth Strong Sales & Client Retention Mail-Order Prescriptions Generic Dispensing Specialty Pharmacy Medicare Business Clinical Leadership - Improving Health Outcomes at Lower Total Healthcare Cost

  5. Slide 5: New-Named & Net-New Sales Performance

    Slide 5: New-Named & Net-New Sales Performance

    New-Named & Net-New Sales Performance *As of second-quarter 2009 earnings call $7.2B Annualized new-named sales Net-new sales $10.1B $5.4B >$8.0B 2008 2009* Completed virtually all of the ~$23 billion in planned 2009 renewals

  6. Slide 6: Early View of 2010 Sales Performance

    Slide 6: Early View of 2010 Sales Performance

    Early View of 2010 Sales Performance *As of second-quarter 2009 earnings call Annualized new-named sales $2.8B 2010* 2010 scheduled and early elective renewals expected to be in the $15 billion to $20 billion range Client retention rate >98%

  7. Slide 7: Mail-Order Script Volume and Growth Opportunity

    Slide 7: Mail-Order Script Volume and Growth Opportunity

    Mail-Order Script Volume and Growth Opportunity Annualized new-named sales ($ in billions) 2005 2006 2007 2008 2009E New Business 4 4.7 2.9 Mail-Order Volume 87 89 95 106 103 Mail-Order Prescription Volume (in millions) Annualized New-Named Sales and Adjusted Mail-Order Penetration 2005 2006 2007 20

  8. Slide 8: Generics Growth Opportunity

    Slide 8: Generics Growth Opportunity

    2008 2009 2010 2011 2012 2013 2014 2015 Acute Chronic/Complex 11.8 13.4 8.8 13.9 23.7 6.1 15 9.9 Generics Growth Opportunity Risperdal(r) Lamictal(r) Fosamax(r) Imitrex(r) Prevacid(r) Topamax(r) Valtrex(r) Adderall XR (r) Effexor XR(r) Flomax(r) Aricept(r) Cozaar(r) Hyzaar(r) Lipitor(r) Actos(r) Lev

  9. Slide 9: Biogenerics Expand Generic Opportunity

    Slide 9: Biogenerics Expand Generic Opportunity

    2011 2012 2013* 2014 2015 2016 2017 Acute Chronic/Complex 13.9 23.7 6.1 15 9.9 4.3 4.8 3.2 2.7 12.1 3.7 10.1 Biogenerics Expand Generic Opportunity ($ in billions) U.S. traditional generic off-patent opportunity $9.3 $17.7 $22.0 U.S. biogeneric off-patent opportunity $8.0 $14.9 Source: U.S. Drug spe

  10. Slide 10: Strong Specialty Pharmacy Growth

    Slide 10: Strong Specialty Pharmacy Growth

    2006 2007 2008 2009E Acute Chronic/Complex 5437 6043 7974 9300 Strong Specialty Pharmacy Growth Accredo Net Revenues $5.4 $9.3+ $8.0 $6.0 Accredo Operating Income 2006 2007 2008 2009E 189 210 281 350 $189 $281 $350+ $210 32% 34% ($ in billions) ($ in millions) 16%+ 25%+

  11. Slide 11: Retiree Solutions - Casting a Broad Net

    Slide 11: Retiree Solutions - Casting a Broad Net

    Retiree Solutions - Casting a Broad Net 2Q09 Medicare PDP revenues up 72.8% from 2Q08 to a record $282.6 million Over 300% growth in total retiree lives for 2009; majority are no risk, ASO contracts Expanding health plan Medicare ASO footprint increases retiree recapture capability and access to new

  12. Slide 12: Clinical Innovations - Medco Therapeutic Resource Centers

    Slide 12: Clinical Innovations - Medco Therapeutic Resource Centers

    Clinical Innovations - Medco Therapeutic Resource Centers(r) Medco Therapeutic Resource Centers(r) (TRCs) Full-service platform, housing specialized pharmacists to deliver superior clinical and financial outcomes for clients and members Focuses on chronic and complex conditions accounting for 96 per

  13. Slide 13: Clinical Innovations - Personalized Medicine

    Slide 13: Clinical Innovations - Personalized Medicine

    Clinical Innovations - Personalized Medicine Pharmacogenomics ("Personalized Medicine") Leveraging the TRC platform, Medco launched two pilots using genetic tests to personalize with precision drug selection/delivery/dosing Collaboration with The Mayo Clinic for Coumadin Collaboration with LabCorp f

  14. Slide 14: International Initiatives

    Slide 14: International Initiatives

    International Initiatives Acquired a majority stake in Netherlands-based Europa Apotheek Venlo, a mail-order pharmacy serving Germany Germany market had 2008 drug spend of $31 billion (Rx) and $6 billion (OTC) Opportunity leverages Medco's core competencies Partnered with Apoteket to create the firs

  15. Slide 15: Strong Balance Sheet and Cash Flows

    Slide 15: Strong Balance Sheet and Cash Flows

    Strong Balance Sheet and Cash Flows Six Months Ended June 2009 Three Months Ended March 2009 Six Months Ended June 2008 Cash and cash equivalents $2,085.5 MM $1,799.5 MM $371.7 MM Cash flow from operations $2,265.5 MM $1,170.3 MM $200.2 MM Capital expenditures $98.1 MM $35.4 MM $87.6 MM Total debt $

  16. Slide 16: Continued Financial Strength in a Weak Economy

    Slide 16: Continued Financial Strength in a Weak Economy

    Continued Financial Strength in a Weak Economy 2009 Guidance* 2009 % Growth over 2008 2008 GAAP Diluted EPS $2.54-$2.59 19%-22% $2.13 Diluted EPS (adj. for intangible amortization) $2.76-$2.81 18%-21% $2.33 *Raised and narrowed guidance range as of second-quarter 2009 earnings call; Previous guidanc

  17. Slide 17: Medco

    Slide 17: Medco

    medco’

  18. Slide 18: Medco's Role in Healthcare Reform

    Slide 18: Medco's Role in Healthcare Reform

    Medco's Role in Healthcare Reform Facts: When you manage drugs better, you manage the whole healthcare system better For prescription drugs, healthcare is wired today Chronic and complex diseases are responsible for 96% of drug costs and 75% of medical expenses in the U.S. For 88% of chronic and com

  19. Slide 19: National Healthcare Reform Agenda

    Slide 19: National Healthcare Reform Agenda

    National Healthcare Reform Agenda Provide benefits for the uninsured Support health information technology initiatives Promote the use of generics Senator Obama sponsored Personalized Medicine Act Provide a pathway for biogenerics/biosimilars Opportunity for Medco Obama Administration Healthcare Obj

  20. Slide 20: Brand and Generic Trend

    Slide 20: Brand and Generic Trend

    Brand and Generic Trend *MAT denotes moving annual total; MAT 08/09 represents the 12 months ending in July 2009. Source: IMS Health, National Prescription Audit Plans, National Sales Perspective, September 2009. Includes re-stated historical data effective with January 2009 update to IMS databases.

  21. Slide 21: Reconciliation Tables

    Slide 21: Reconciliation Tables

    Reconciliation Tables Medco Health Solutions, Inc. Selected Information (Unaudited) Full Years Ended Full Years Ended Earnings Per Share Reconciliation December 29, 2007 December 30, 2006 GAAP diluted earnings per share $1.63 $1.04 Adjustment for the 2006 legal settlements charge1 - $0.17 Diluted ea

  22. Slide 22: Reconciliation Tables

    Slide 22: Reconciliation Tables

    Reconciliation Tables Medco Health Solutions, Inc. Selected Information (Unaudited) Full Years Ended Full Years Ended Estimated Full Year Ended December 26, 2009 Estimated Full Year Ended December 26, 2009 Earnings Per Share Guidance Reconciliation December 29, 2007 December 27, 2008 Low End High En

Source: SEC EDGAR · 8-K filed Sep 11, 2009

More decks from Medco Health Solutions Inc